NCT00595322

Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma

Safety of Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma: A Pilot Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a pilot study. The goal of this study is to test whether Bevacizumab is safe enough in patients with brain tumors so that a larger study can be conducted. This study will also give us some information about whether the combination of Bevacizumab and radiation has potential to become an effective treatment for regrowing brain tumors. Bevacizumab is an experimental drug that blocks a molecule called VEGF that is found in high amounts in malignant gliomas. VEGF promotes the growth of blood vessels that bring nutrients to tumor cells. In studies with laboratory animals, Bevacizumab slowed the growth of several different types of human cancer cells by blocking the effects of VEGF. There is also evidence that Bevacizumab enhances the effects of radiation on tumor cell

Conditions

• Brain Cancer
• Recurrent Malignant Gliomas
• Primary Brain Tumor

Interventions

Type	Name	Description
OTHER	bevacizumab and radiation (IMRT)	bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains \< 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)

Timeline

• Start date: 2005-12-01
• Primary completion: 2017-05-01
• Completion: 2017-05-01
• First posted: 2008-01-16
• Last updated: 2017-05-23

Locations

2 sites across 1 country: United States